All these evidences prompted us to investigate the role of SYK in ETV6-RUNX1 cell survival and prognosis, trying to elucidate molecular mechanisms responsible for drug resistance and relapse occurrence in this otherwise good-prognosis B-ALL subtype. Here, RUNX1 is linked to acute lymphoblastic leukemia.